JP2023521273A - ウシ前駆細胞を培養する為の無血清培地 - Google Patents
ウシ前駆細胞を培養する為の無血清培地 Download PDFInfo
- Publication number
- JP2023521273A JP2023521273A JP2022547049A JP2022547049A JP2023521273A JP 2023521273 A JP2023521273 A JP 2023521273A JP 2022547049 A JP2022547049 A JP 2022547049A JP 2022547049 A JP2022547049 A JP 2022547049A JP 2023521273 A JP2023521273 A JP 2023521273A
- Authority
- JP
- Japan
- Prior art keywords
- serum
- free medium
- medium
- progenitor cells
- bovine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012679 serum free medium Substances 0.000 title claims abstract description 222
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 195
- 241000283690 Bos taurus Species 0.000 title claims abstract description 144
- 238000012258 culturing Methods 0.000 title claims abstract description 29
- 102000009027 Albumins Human genes 0.000 claims abstract description 30
- 108010088751 Albumins Proteins 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000002609 medium Substances 0.000 claims description 105
- 239000007640 basal medium Substances 0.000 claims description 82
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 62
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 62
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 62
- 210000003205 muscle Anatomy 0.000 claims description 58
- 102000004889 Interleukin-6 Human genes 0.000 claims description 57
- 108090001005 Interleukin-6 Proteins 0.000 claims description 57
- 229940100601 interleukin-6 Drugs 0.000 claims description 57
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 52
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 52
- 102000013275 Somatomedins Human genes 0.000 claims description 52
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 48
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 47
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 47
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 47
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 46
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 46
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 45
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 45
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 44
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 39
- 239000003531 protein hydrolysate Substances 0.000 claims description 39
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims description 38
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 36
- 230000000035 biogenic effect Effects 0.000 claims description 36
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 35
- 239000008103 glucose Substances 0.000 claims description 35
- 239000003102 growth factor Substances 0.000 claims description 35
- 150000001412 amines Chemical class 0.000 claims description 34
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 32
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 32
- 239000000194 fatty acid Substances 0.000 claims description 32
- 229930195729 fatty acid Natural products 0.000 claims description 32
- 150000004665 fatty acids Chemical class 0.000 claims description 32
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 30
- 210000000577 adipose tissue Anatomy 0.000 claims description 29
- 108091006975 Iron transporters Proteins 0.000 claims description 27
- 229910052742 iron Inorganic materials 0.000 claims description 26
- 229940088597 hormone Drugs 0.000 claims description 25
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 24
- 102000004127 Cytokines Human genes 0.000 claims description 24
- 108090000695 Cytokines Proteins 0.000 claims description 24
- 229960000890 hydrocortisone Drugs 0.000 claims description 24
- 239000005556 hormone Substances 0.000 claims description 23
- 230000035755 proliferation Effects 0.000 claims description 23
- 102000004877 Insulin Human genes 0.000 claims description 22
- 108090001061 Insulin Proteins 0.000 claims description 22
- 229940125396 insulin Drugs 0.000 claims description 22
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 21
- 108010051696 Growth Hormone Proteins 0.000 claims description 20
- 238000004113 cell culture Methods 0.000 claims description 20
- 239000011781 sodium selenite Substances 0.000 claims description 20
- 229960001471 sodium selenite Drugs 0.000 claims description 20
- 235000015921 sodium selenite Nutrition 0.000 claims description 20
- 229940088594 vitamin Drugs 0.000 claims description 20
- 229930003231 vitamin Natural products 0.000 claims description 20
- 235000013343 vitamin Nutrition 0.000 claims description 20
- 239000011782 vitamin Substances 0.000 claims description 20
- 229940063673 spermidine Drugs 0.000 claims description 19
- 235000010323 ascorbic acid Nutrition 0.000 claims description 18
- 239000011668 ascorbic acid Substances 0.000 claims description 18
- 229960005070 ascorbic acid Drugs 0.000 claims description 18
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 17
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 17
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 16
- 229940063675 spermine Drugs 0.000 claims description 15
- 108010073771 Soybean Proteins Proteins 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229940001941 soy protein Drugs 0.000 claims description 10
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 9
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims description 9
- 229960004488 linolenic acid Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000005700 Putrescine Substances 0.000 claims description 8
- 239000012979 RPMI medium Substances 0.000 claims description 5
- 235000013622 meat product Nutrition 0.000 claims description 5
- 102000018997 Growth Hormone Human genes 0.000 claims 4
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 25
- 210000002950 fibroblast Anatomy 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 68
- 238000012136 culture method Methods 0.000 description 50
- 210000002966 serum Anatomy 0.000 description 26
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 18
- 102100038803 Somatotropin Human genes 0.000 description 16
- 239000000306 component Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 239000004017 serum-free culture medium Substances 0.000 description 15
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 13
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 108010081589 Becaplermin Proteins 0.000 description 10
- 235000010469 Glycine max Nutrition 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 241001494479 Pecora Species 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 7
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 7
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 7
- 229960002648 alanylglutamine Drugs 0.000 description 7
- 241000282817 Bovidae Species 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 6
- 102100037362 Fibronectin Human genes 0.000 description 6
- 108010067306 Fibronectins Proteins 0.000 description 6
- 241000282887 Suidae Species 0.000 description 6
- 102000004338 Transferrin Human genes 0.000 description 6
- 108090000901 Transferrin Proteins 0.000 description 6
- 210000001789 adipocyte Anatomy 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 229920000768 polyamine Polymers 0.000 description 6
- 239000012581 transferrin Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000012533 medium component Substances 0.000 description 5
- 210000000663 muscle cell Anatomy 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 210000004504 adult stem cell Anatomy 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 3
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 102100025304 Integrin beta-1 Human genes 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 210000001087 myotubule Anatomy 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 210000002363 skeletal muscle cell Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000005167 vascular cell Anatomy 0.000 description 3
- 101150021185 FGF gene Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 102000057308 human HGF Human genes 0.000 description 2
- 102000044162 human IGF1 Human genes 0.000 description 2
- 102000052611 human IL6 Human genes 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 2
- 239000012092 media component Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 241000282813 Aepyceros melampus Species 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 235000012137 Atriplex confertifolia Nutrition 0.000 description 1
- 244000266618 Atriplex confertifolia Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283726 Bison Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000283716 Connochaetes Species 0.000 description 1
- 241000283899 Gazella Species 0.000 description 1
- 241000282375 Herpestidae Species 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100281008 Homo sapiens FGF2 gene Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 description 1
- 101000601661 Homo sapiens Paired box protein Pax-7 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100040891 Paired box protein Pax-3 Human genes 0.000 description 1
- 102100037503 Paired box protein Pax-7 Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003055 full factorial design Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- -1 mono- or polyamines Chemical class 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000518 sarcolemma Anatomy 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0031—Serum-free culture media
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
- B63B—SHIPS OR OTHER WATERBORNE VESSELS; EQUIPMENT FOR SHIPPING
- B63B21/00—Tying-up; Shifting, towing, or pushing equipment; Anchoring
- B63B21/16—Tying-up; Shifting, towing, or pushing equipment; Anchoring using winches
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
- B63B—SHIPS OR OTHER WATERBORNE VESSELS; EQUIPMENT FOR SHIPPING
- B63B79/00—Monitoring properties or operating parameters of vessels in operation
- B63B79/10—Monitoring properties or operating parameters of vessels in operation using sensors, e.g. pressure sensors, strain gauges or accelerometers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F03—MACHINES OR ENGINES FOR LIQUIDS; WIND, SPRING, OR WEIGHT MOTORS; PRODUCING MECHANICAL POWER OR A REACTIVE PROPULSIVE THRUST, NOT OTHERWISE PROVIDED FOR
- F03D—WIND MOTORS
- F03D13/00—Assembly, mounting or commissioning of wind motors; Arrangements specially adapted for transporting wind motor components
- F03D13/20—Arrangements for mounting or supporting wind motors; Masts or towers for wind motors
- F03D13/25—Arrangements for mounting or supporting wind motors; Masts or towers for wind motors specially adapted for offshore installation
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F03—MACHINES OR ENGINES FOR LIQUIDS; WIND, SPRING, OR WEIGHT MOTORS; PRODUCING MECHANICAL POWER OR A REACTIVE PROPULSIVE THRUST, NOT OTHERWISE PROVIDED FOR
- F03D—WIND MOTORS
- F03D7/00—Controlling wind motors
- F03D7/02—Controlling wind motors the wind motors having rotation axis substantially parallel to the air flow entering the rotor
- F03D7/04—Automatic control; Regulation
- F03D7/042—Automatic control; Regulation by means of an electrical or electronic controller
- F03D7/048—Automatic control; Regulation by means of an electrical or electronic controller controlling wind farms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
- B63B—SHIPS OR OTHER WATERBORNE VESSELS; EQUIPMENT FOR SHIPPING
- B63B21/00—Tying-up; Shifting, towing, or pushing equipment; Anchoring
- B63B21/50—Anchoring arrangements or methods for special vessels, e.g. for floating drilling platforms or dredgers
- B63B2021/505—Methods for installation or mooring of floating offshore platforms on site
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
- B63B—SHIPS OR OTHER WATERBORNE VESSELS; EQUIPMENT FOR SHIPPING
- B63B35/00—Vessels or similar floating structures specially adapted for specific purposes and not otherwise provided for
- B63B35/44—Floating buildings, stores, drilling platforms, or workshops, e.g. carrying water-oil separating devices
- B63B2035/4433—Floating structures carrying electric power plants
- B63B2035/446—Floating structures carrying electric power plants for converting wind energy into electric energy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/99—Serum-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/12—Hepatocyte growth factor [HGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F05—INDEXING SCHEMES RELATING TO ENGINES OR PUMPS IN VARIOUS SUBCLASSES OF CLASSES F01-F04
- F05B—INDEXING SCHEME RELATING TO WIND, SPRING, WEIGHT, INERTIA OR LIKE MOTORS, TO MACHINES OR ENGINES FOR LIQUIDS COVERED BY SUBCLASSES F03B, F03D AND F03G
- F05B2240/00—Components
- F05B2240/90—Mounting on supporting structures or systems
- F05B2240/93—Mounting on supporting structures or systems on a structure floating on a liquid surface
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F05—INDEXING SCHEMES RELATING TO ENGINES OR PUMPS IN VARIOUS SUBCLASSES OF CLASSES F01-F04
- F05B—INDEXING SCHEME RELATING TO WIND, SPRING, WEIGHT, INERTIA OR LIKE MOTORS, TO MACHINES OR ENGINES FOR LIQUIDS COVERED BY SUBCLASSES F03B, F03D AND F03G
- F05B2270/00—Control
- F05B2270/10—Purpose of the control system
- F05B2270/20—Purpose of the control system to optimise the performance of a machine
- F05B2270/204—Purpose of the control system to optimise the performance of a machine taking into account the wake effect
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F05—INDEXING SCHEMES RELATING TO ENGINES OR PUMPS IN VARIOUS SUBCLASSES OF CLASSES F01-F04
- F05B—INDEXING SCHEME RELATING TO WIND, SPRING, WEIGHT, INERTIA OR LIKE MOTORS, TO MACHINES OR ENGINES FOR LIQUIDS COVERED BY SUBCLASSES F03B, F03D AND F03G
- F05B2270/00—Control
- F05B2270/30—Control parameters, e.g. input parameters
- F05B2270/331—Mechanical loads
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E10/00—Energy generation through renewable energy sources
- Y02E10/70—Wind energy
- Y02E10/72—Wind turbines with rotation axis in wind direction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E10/00—Energy generation through renewable energy sources
- Y02E10/70—Wind energy
- Y02E10/727—Offshore wind turbines
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mechanical Engineering (AREA)
- Combustion & Propulsion (AREA)
- Ocean & Marine Engineering (AREA)
- Sustainable Development (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Sustainable Energy (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本発明は、動物細胞培養の為の無血清培地、より特には、ウシ前駆細胞、例えば(骨格)筋組織由来前駆細胞及び脂肪組織由来前駆細胞を包含するウシ前駆細胞、を培養する方法において用いる為の無血清培地、の分野である。本発明はまた、本発明の培地を用いてウシ前駆細胞を培養する方法に関する。より特には、本発明の無血清培地は、そのような前駆細胞の増殖(proliferation)(拡大(expansion))に用いられることができる。
本発明者等は、ヒト以外の哺乳類前駆細胞、特にウシ前駆細胞、例えばウシ筋組織由来前駆細胞(bovine muscle tissue-derived progenitor cells)及びウシ脂肪組織由来前駆細胞(bovine adipose tissue-derived progenitor cells)、の培養及び増殖(proliferation)(拡大(expansion))に用いることができる無血清培地を見いだした。
定義
本発明は、アルブミン及び線維芽細胞成長因子(FGF)を含む、ウシ前駆細胞を培養する為の無血清培地を提供する。代替的には、本発明は、アルブミン;並びに、本明細書に記載されている1以上の成長因子及び/又はサイトカイン、好ましくは少なくとも線維芽細胞成長因子(FGF)、を含む、ウシ前駆細胞を培養する為の無血清培地を提供する。該線維芽細胞成長因子(FGF)は、好ましくはヒトFGF、より好ましくはヒトFGF basic(FGFb、FGF2とまた称される)、更により好ましくはヒト組換えFGF basic、例えばR&D Systems社製の233-FB、である。好ましくは、該アルブミンはヒトアルブミンであり、例えばBiorbyt社(orb419911)から入手される、組換えヒトアルブミン等である。該アルブミンは、0.01~100g/l、好ましくは0.01~50g/l、より好ましくは0.1~10g/l、より好ましくは0.5~5g/l、例えば約5g/l、の濃度で該培地中に存在することができる。該FGFは、0.1~1000μg/l、好ましくは1~100μg/l、より好ましくは5~50μg/l、更により好ましくは約10μg/l、の濃度で該培地中に存在することができる。
本発明はまた、ウシ前駆細胞を培養する方法であって、本発明の無血清培地中でウシ前駆細胞を培養する工程を含む上記の方法を提供する。
アルブミン、及び
線維芽細胞成長因子(FGF)
を含む上記の前駆細胞培養用の無血清培地。
を含む、実施態様1~16のうちのいずれか1つに記載された培地を製造する方法。
実施例1. 本発明の無血清培地の製造
材料及び方法
ウシ筋前駆細胞は、ウシ筋組織(ウシ(Bos taurus))から単離され、過去に記載されているCD29の陽性発現に基づいて選別された(Ding et al., Sci. Rep., 17(8): 10808 (2018))。
図2には、血清含有対照と比較した該細胞の相対的な成長(百分率として表す)が示されている。これらの結果の統計解析では、IGF1及びVEGFの添加による有意な正の効果とともに、IGF1とHGFとの正の相乗効果が示された。IGF1を100μg/l、HGFを5μg/l、VEGFを10μg/l、及びPDGF-BBを10μg/l添加した該無血清培地は、該血清含有対照と比較して1.5倍の成長を示し、無血清ベースの対照(成長因子として5ng/ml FGF及び75ng/ml IL-6のみを含む)と比較して4.7倍の成長を示した。
材料及び方法
ウシ筋前駆細胞は、ウシ筋組織(ウシ(Bos taurus))から単離され、過去に記載されているCD29の陽性発現に基づいて選別された(Ding et al., Sci. Rep., 17(8): 10808 (2018))。
該血清含有培地中で培養させた筋前駆細胞は、初期の成長率が高く、この成長率が時間とともに減少したのに対して、無血清成長細胞は、成長率が低く、この成長率が比較的一定(より安定)していた。時間とともに、2種の培地中の細胞の全成長は、同程度であった。図3を参照されたい。
材料及び方法
全てウシ(Bos taurus)由来の衛星細胞及び脂肪組織前駆細胞、例えば、間質血管細胞群(SVF)細胞は、コラーゲン被覆96穴プレートに播種され、95%空気/5% CO2の加湿雰囲気中、37℃で、種々の基礎培地(すなわち、RPMI培地(11875093、Thermo Fischer Scientific社製)、アルファ-MEM培地(12561056、Thermo Fischer Scientific社製)、全て上述のF12を用いて作製された、F12培地(11765054、Thermo Fischer Scientific社製)、DMEM/F12 1:1培地、DMEM/F12 10:1培地、及びDMEM/F12 1:10培地)、並びにDMEM(A1443001、Thermo Fischer Scientific社製)を含む、アルブミン(5mg/ml)、ソマトトロピン(2ng/ml)、L-アスコルビン酸2-リン酸(50μg/ml)、ヒドロコルチゾン(36ng/ml)、α-リノレン酸(1μg/ml)、インスリン(10μg/ml)、トランスフェリン(5.5μg/ml)、亜セレン酸ナトリウム(0.0067μg/ml)、エタノールアミン(2μg/ml)、L-アラニル-L-グルタミン又はグルタミン(2mM)、IL-6(5ng/ml)、bFGFとまた称されるFGF2(10ng/ml)、IGF1(100ng/ml)、VEGF(10ng/ml)、HGF(5ng/ml)、PDGF-BB(10ng/ml)からなる本発明の無血清培地中で、6日間培養させた。培養6日後に、該細胞は、ハイコンテンツアナライザーImageXpress Pico Automated Cell Imaging Systemにより計数された。相対成長率は、特定の培地における細胞数を日数で割って、対照(DMEM:F12中の成長)に正規化することにより、算出された。
衛星細胞及び脂肪組織前駆細胞の効果的な成長(growth)(増殖(proliferation))率は、種々の基礎培地のスペクトルを含む本発明の無血清培地により達成され、そのような細胞の成長(growth)(増殖(proliferation))率は、特定の基礎培地に依存しないことが観察された(図7)。
Claims (19)
- ウシ前駆細胞を培養する方法であって、
ウシ前駆細胞を培養する為の無血清培地中でウシ前駆細胞を培養する工程を含み、
ここで、前記無血清培地が、
アルブミン、及び
線維芽細胞成長因子(FGF)
を含む、前記方法。 - 前記無血清培地が、
アスコルビン酸又はその誘導体、インスリン、ソマトトロピン及びヒドロコルチゾンからなる群より選択されるビタミン及び/又はホルモンのうちの1以上;並びに、
血小板由来成長因子(PDGF)、インスリン様成長因子(IGF)、血管内皮成長因子(VEGF)、肝細胞成長因子(HGF)及びインターロイキン6(IL-6)からなる群より選択される1以上のサイトカイン及び/又は成長因子
を更に含む、請求項1に記載の方法。 - 前記無血清培地が、前記1以上のサイトカイン及び/又は成長因子として、
IL-6;
IL-6及びIGF;
IL-6、IGF及びHGF;
IL-6、IGF、HGF及びPDGF;
IL-6、IGF及びVEGF;
IL-6、IGF及びPDGF;
IL-6、PDGF及びVEGF;
IL-6、IGF、PDGF及びVEGF;又は
IL-6、IGF、HGF、PDGF及びVEGF
を含む、請求項2に記載の方法。 - 前記無血清培地が、
アスコルビン酸又はその誘導体、インスリン、ソマトトロピン、及びヒドロコルチゾン、並びに、
PDGF、VEGF、HGF、IGF及びIL-6
を含む、請求項1~3のいずれか1項に記載の方法。 - 前記無血清培地が更に、
基礎培地、
グルコース源、
グルタミン源、
脂肪酸源、
鉄源又は鉄輸送体、及び/又は
亜セレン酸ナトリウム
を含む、請求項1~4のいずれか1項に記載の方法。 - 前記基礎培地が、(i)DMEM及び/又はハムF12(Ham’s F12)培地、好ましくは、DMEM及びハムF12培地をそれぞれ、例えば1:10~10:1、より好ましくは1:1、の比、(ii)RPMI培地、及び/又は(iii)アルファ-MEM培地を含む、請求項5に記載の方法。
- 前記脂肪酸源がα-リノレン酸を含む、請求項5又は6に記載の方法。
- 前記無血清培地が更に、タンパク質加水分解物、好ましくは大豆タンパク質加水分解物を含む、請求項1~7のいずれか1項に記載の方法。
- 前記無血清培地が更に、生体アミンを含み、好ましくは、エタノールアミン、プトレシン、スペルミジン及び/又はスペルミンを含む、請求項1~8のいずれか1項に記載の方法。
- ウシ前駆細胞を培養する方法であって、ウシ前駆細胞を培養する為の無血清培地中でウシ前駆細胞を培養する工程を含み、ここで、該無血清培地が、
アルブミン、
線維芽細胞成長因子(FGF)
アスコルビン酸又はその誘導体、インスリン、ソマトトロピン及びヒドロコルチゾンからなる群より選択されるビタミン及び/又はホルモンのうちの1以上、
血小板由来成長因子(PDGF)、インスリン様成長因子(IGF)、血管内皮成長因子(VEGF)、肝細胞成長因子(HGF)及びインターロイキン6(IL-6)からなる群より選択される1以上のサイトカイン及び/又は成長因子、
基礎培地、
グルコース源、
グルタミン源、
脂肪酸源、
鉄源又は鉄輸送体、及び
亜セレン酸ナトリウム、並びに、
任意的に、タンパク質加水分解物、生体アミン及び/又は付着因子
を含む、前記方法。 - 前記アルブミン、前記FGF、前記1以上のサイトカイン及び/又は成長因子、前記ビタミン及び/又はホルモンのうちの1以上、前記基礎培地、前記グルコース源、前記グルタミン源、前記脂肪酸源、前記鉄源又は鉄輸送体、及び前記亜セレン酸ナトリウム、前記タンパク質加水分解物、前記生体アミン及び/又は前記付着因子が、培養中のウシ前駆細胞の増殖に有効な量で存在する、請求項1~10のいずれか1項に記載の方法。
- 前記無血清培地が、ウシ前駆細胞の為の無血清培地である、請求項1~11のいずれか1項に記載の方法。
- 請求項1~12のいずれか1項に定義されている無血清培地と、ウシ前駆細胞とを含む組成物。
- ウシ前駆細胞を培養する為の無血清培地であって、
アルブミン、及び
線維芽細胞成長因子(FGF)
を含む、前記無血清培地。 - 前記無血清培地が更に、IL-6を含む、請求項14に記載の無血清培地。
- 前記無血清培地が、請求項2~12のいずれか1項に定義されている無血清培地である、請求項14又は15に記載の無血清培地。
- 前記無血清培地が更に、
タンパク質加水分解物、好ましくは大豆タンパク質加水分解物
DMEM及びハムF12培地を含む基礎培地、
ソマトトロピン、
ヒドロコルチゾン、
スペルミン、及び/又は
スペルミジン
を含む、請求項14~16のいずれか1項に記載の無血清培地。 - 前記ウシ前駆細胞が、ウシ筋前駆細胞又はウシ脂肪(脂肪組織)前駆細胞である、請求項1~12のいずれか1項に記載の方法、又は請求項13に記載の組成物、又は請求項14~17のいずれか1項に記載の無血清培地。
- 細胞培養ベースのヒト食用食肉製品の製造における、請求項14~17のいずれか1項に記載の無血清培地を使用する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20386007 | 2020-02-03 | ||
EP20386007.7 | 2020-02-03 | ||
PCT/NL2021/050066 WO2021158103A1 (en) | 2020-02-03 | 2021-02-03 | Serum-free medium for culturing a bovine progenitor cell. |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023521273A true JP2023521273A (ja) | 2023-05-24 |
JPWO2021158103A5 JPWO2021158103A5 (ja) | 2023-07-19 |
Family
ID=69713983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022547049A Withdrawn JP2023521273A (ja) | 2020-02-03 | 2021-02-03 | ウシ前駆細胞を培養する為の無血清培地 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230083026A1 (ja) |
EP (1) | EP4100432A1 (ja) |
JP (1) | JP2023521273A (ja) |
CN (1) | CN115298211A (ja) |
BR (1) | BR112022014600A2 (ja) |
IL (1) | IL294945A (ja) |
WO (1) | WO2021158103A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL2028813B1 (en) | 2021-07-22 | 2023-01-27 | Mosa Meat B V | Serum-free media for producing adipocytes for animal consumption. |
AU2022369299A1 (en) | 2021-10-19 | 2024-03-14 | Eat Scifi Inc. | Plant base/animal cell hybrid meat substitute |
WO2024007033A1 (en) * | 2022-07-01 | 2024-01-04 | Good Meat, Inc. | Cultivated animal cells adapted for growth in low amounts, and/or the absence of, direct growth factors, indirect growth factors, animal serum, and/or animal components, and methods of use thereof |
NL2032514B1 (en) | 2022-07-15 | 2024-01-25 | Mosa Meat B V | Method of generating a homocellular progenitor cell culture from a heterocellular tissue sample |
CN116396930B (zh) * | 2023-06-08 | 2023-09-22 | 北京华龛生物科技有限公司 | 间充质干细胞无血清培养基及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6617159B1 (en) * | 1998-11-09 | 2003-09-09 | Consorzio Per La Gestione Del Centro Di Biotechnologie Avanzate | Serum free medium for chondrocyte cells |
EP1988159B1 (en) * | 2006-01-13 | 2014-03-05 | Two Cells Co., Ltd. | Additive for culture medium for use in serum-free culture of animal cell, kit, and use of the additive or kit |
US9139814B2 (en) * | 2008-09-22 | 2015-09-22 | Universite Laval | Culture medium for myoblasts, precursors thereof and derivatives thereof |
WO2010055616A1 (ja) * | 2008-11-11 | 2010-05-20 | 独立行政法人科学技術振興機構 | 分化誘導培地用添加剤およびその利用 |
CN105112364B (zh) * | 2015-08-18 | 2019-04-02 | 广东美赛尔细胞生物科技有限公司 | 人脂肪间充质干细胞的无血清培养基及其制备方法 |
CN109714962A (zh) * | 2016-07-11 | 2019-05-03 | 耶路撒冷希伯来大学的益生研究开发有限公司 | 用于在体外培养细胞的系统和方法 |
-
2021
- 2021-02-03 EP EP21704034.4A patent/EP4100432A1/en active Pending
- 2021-02-03 JP JP2022547049A patent/JP2023521273A/ja not_active Withdrawn
- 2021-02-03 CN CN202180011683.9A patent/CN115298211A/zh active Pending
- 2021-02-03 IL IL294945A patent/IL294945A/en unknown
- 2021-02-03 BR BR112022014600A patent/BR112022014600A2/pt unknown
- 2021-02-03 WO PCT/NL2021/050066 patent/WO2021158103A1/en unknown
- 2021-02-03 US US17/759,423 patent/US20230083026A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115298211A (zh) | 2022-11-04 |
IL294945A (en) | 2022-09-01 |
WO2021158103A1 (en) | 2021-08-12 |
EP4100432A1 (en) | 2022-12-14 |
BR112022014600A2 (pt) | 2022-09-27 |
US20230083026A1 (en) | 2023-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023521273A (ja) | ウシ前駆細胞を培養する為の無血清培地 | |
CN108251359B (zh) | 一种间充质干细胞无血清培养基及培养方法 | |
Choi et al. | Muscle stem cell isolation and in vitro culture for meat production: A methodological review | |
EP1988159B1 (en) | Additive for culture medium for use in serum-free culture of animal cell, kit, and use of the additive or kit | |
US20180163177A1 (en) | Serum-free culture medium and method for expanding hematopoietic stem cells | |
JP7410899B2 (ja) | 間葉系幹細胞の細胞培養法 | |
CN111206017B (zh) | 一种干细胞无血清培养基及其应用 | |
US20230117670A1 (en) | Bioactive substance composition, serum-free medium comprising the composition, and uses thereof | |
WO2021254296A1 (zh) | 一种生物活性物质组合物、包含所述组合物的无血清培养基及其用途 | |
TW200927927A (en) | Stem cell medium | |
CN111440764B (zh) | 间充质干细胞的无血清培养基及间充质干细胞的临床级规模化培养方法 | |
KR20210044749A (ko) | 무혈청 배지 조성물 | |
US20240010984A1 (en) | Serum-free medium for differentiation of a progenitor cell | |
US20080081370A1 (en) | Directed differentiation of human embryonic stem cells into mesenchymal/stromal cells | |
NL2032514B1 (en) | Method of generating a homocellular progenitor cell culture from a heterocellular tissue sample | |
CN115537388A (zh) | 一种适用于细胞培养肉的牛脂肪间充质干细胞无血清培养基及其制备方法 | |
Hoshi et al. | Growth requirements and long-term subcultivation of bovine granulosa cells cultured in a serum-free medium | |
Kitano | Serum‐free media | |
US20190177686A1 (en) | Medium, additive for albumin-free medium, and method for culturing pluripotent stem cells | |
CN117535237A (zh) | 人脐带间充质干细胞培养基及其制备方法 | |
JP2014183784A (ja) | ヒト造血幹細胞を増幅させるための組成物及び方法 | |
CN112322581A (zh) | 组合物及其应用、细胞培养基及间充质干细胞的复苏方法 | |
CN117264888A (zh) | 一种制备造血干细胞和祖细胞的方法 | |
CN117778301A (zh) | 一种无血清培养基及其在细胞培养肉中的应用 | |
Collodi et al. | Serum-free media |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230707 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231227 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20240104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240119 |